BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19123011)

  • 1. Response to the expertise: procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen.
    Koch K; Lange S
    Eur J Health Econ; 2009 May; 10(2):233-6. PubMed ID: 19123011
    [No Abstract]   [Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany: give the child a name.
    Schünemann H; Kunz R; Falck-Ytter Y; Santesso N
    Eur J Health Econ; 2009 May; 10(2):237-8. PubMed ID: 19290557
    [No Abstract]   [Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 2].
    Schünemann HJ; Kunz R; Falck-Ytter Y
    Dtsch Med Wochenschr; 2009 Feb; 134(7):319-20; author reply 320. PubMed ID: 19197817
    [No Abstract]   [Full Text] [Related]  

  • 5. [Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 1].
    Koch K; Lange S
    Dtsch Med Wochenschr; 2009 Feb; 134(7):317-9; author reply 320. PubMed ID: 19197816
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reform in evidence based medicine. Where is solidarity?].
    el-Din MD
    MMW Fortschr Med; 2002 Dec; 144(50):18. PubMed ID: 14610861
    [No Abstract]   [Full Text] [Related]  

  • 7. [New EBM: is it really so detrimental to physicians?].
    Schmidt K
    MMW Fortschr Med; 2004 Sep; 146(39):56-7. PubMed ID: 15532417
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value-based medicine in ophthalmology].
    Finger RP
    Ophthalmologe; 2010 Mar; 107(3):213. PubMed ID: 20024565
    [No Abstract]   [Full Text] [Related]  

  • 9. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Resources for prevention?].
    MMW Fortschr Med; 2006 Dec; 148(51-52):62-3. PubMed ID: 17619351
    [No Abstract]   [Full Text] [Related]  

  • 11. [What is evidence-based?].
    Gerlach H
    Krankenpfl J; 2005; 43(1-3):54-5. PubMed ID: 15912843
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
    Müller T
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evidence-based surgery. What is really verified?].
    Jähne J
    Chirurg; 2011 Dec; 82(12):1065-6. PubMed ID: 22090012
    [No Abstract]   [Full Text] [Related]  

  • 14. [The future of German surgery lies in documentation by transparent outcome quality].
    Sawicki PT
    Chirurg; 2008 Nov; Suppl():371-2. PubMed ID: 19367751
    [No Abstract]   [Full Text] [Related]  

  • 15. [Significance of evidence-based decisions for health policy].
    Pientka L
    Med Klin (Munich); 1996 Aug; 91(8):541-6. PubMed ID: 8965756
    [No Abstract]   [Full Text] [Related]  

  • 16. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evidence-based medicine expanded. New general practice number in the established point value].
    MMW Fortschr Med; 2002 Sep; 144(38):52-3. PubMed ID: 12395706
    [No Abstract]   [Full Text] [Related]  

  • 18. [References and information on the EMB-2000plus concept].
    Köhler A
    Urologe A; 2003 Jan; 42(1):140-5. PubMed ID: 14655651
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.